- Home
- PWM vs APRE Comparison
PWM vs APRE Comparison
Compare PWM & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- APRE
- Stock Information
- Founded
- PWM 2018
- APRE 2006
- Country
- PWM Hong Kong
- APRE United States
- Employees
- PWM N/A
- APRE N/A
- Industry
- PWM
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PWM
- APRE Health Care
- Exchange
- PWM Nasdaq
- APRE Nasdaq
- Market Cap
- PWM 12.4M
- APRE 10.0M
- IPO Year
- PWM 2023
- APRE 2019
- Fundamental
- Price
- PWM $0.40
- APRE $1.99
- Analyst Decision
- PWM
- APRE Strong Buy
- Analyst Count
- PWM 0
- APRE 2
- Target Price
- PWM N/A
- APRE $15.50
- AVG Volume (30 Days)
- PWM 6.3M
- APRE 68.4K
- Earning Date
- PWM 07-29-2025
- APRE 08-11-2025
- Dividend Yield
- PWM N/A
- APRE N/A
- EPS Growth
- PWM N/A
- APRE N/A
- EPS
- PWM N/A
- APRE N/A
- Revenue
- PWM $639,912.00
- APRE $1,284,475.00
- Revenue This Year
- PWM N/A
- APRE N/A
- Revenue Next Year
- PWM N/A
- APRE N/A
- P/E Ratio
- PWM N/A
- APRE N/A
- Revenue Growth
- PWM 83.60
- APRE 33.27
- 52 Week Low
- PWM $0.31
- APRE $1.41
- 52 Week High
- PWM $2.70
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- PWM 50.05
- APRE 54.45
- Support Level
- PWM $0.38
- APRE $1.60
- Resistance Level
- PWM $0.43
- APRE $1.80
- Average True Range (ATR)
- PWM 0.04
- APRE 0.12
- MACD
- PWM -0.00
- APRE 0.00
- Stochastic Oscillator
- PWM 42.17
- APRE 51.49
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.